Study search
Go straight to the source
Search PubMed, Europe PMC and ClinicalTrials.gov from one box. Results come from the indexes themselves, newest first, each linked to its original record.
Amiravo's reviewed summary: Ecnoglutide research reference →
16 records · open this search in PubMed
- PubMedDevelopment and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.Journal of chromatography. A · 2026 Oct 11
- PubMedSystematic ReviewMeta-AnalysisDose-response and time-course effects of ecnoglutide in type 2 diabetes: a systematic review and meta-analysis of efficacy.Frontiers in endocrinology · 2026
- PubMedReviewEcnoglutide: First Approvals.Drugs · 2026 Sep
- PubMedClinical Trial, Phase IEffect of a Novel GLP-1 Analogue Ecnoglutide on the Pharmacokinetics of Rosuvastatin and Digoxin in Healthy Participants.Diabetes, obesity & metabolism · 2026 Sep
- PubMedReviewEvaluating the therapeutic benefits and safety of ecnoglutide for type 2 diabetes: evidence from a systematic review and meta-analysis.Diabetology & metabolic syndrome · 2026 Jul 27
- PubMedSystematic ReviewNetwork Meta-AnalysisComparative StudyComparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2026 Jul 8
- PubMedSystematic ReviewMeta-AnalysisComparative StudyComparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2026 May
- PubMedNo dose adjustment required for warfarin or metformin when coadministered with the novel GLP-1 receptor agonist ecnoglutide: an open-label, fixed-sequence, crossover study.Frontiers in pharmacology · 2026
- PubMedRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIIEfficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial.Nature communications · 2026 Jan 7
- PubMedEcnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?The lancet. Diabetes & endocrinology · 2025 Oct
- PubMedMulticenter StudyRandomized Controlled TrialClinical Trial, Phase IIIEfficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial.The lancet. Diabetes & endocrinology · 2025 Oct
- PubMedRandomized Controlled TrialMulticenter StudyClinical Trial, Phase IIIEfficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.The lancet. Diabetes & endocrinology · 2025 Sep
- PubMedReviewEfficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare.World journal of cardiology · 2025 Aug 26
- PubMedSystematic ReviewEmerging pharmacotherapies for obesity: A systematic review.Pharmacological reviews · 2025 Jan
- PubMedRandomized Controlled TrialClinical Trial, Phase IIMulticenter StudyEfficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial.Nature communications · 2024 Sep 27
- PubMedRandomized Controlled TrialClinical Trial, Phase IDiscovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog.Molecular metabolism · 2023 Sep
Queries go directly from your browser to NCBI, EMBL-EBI and ClinicalTrials.gov; Amiravo does not store them. Study-type labels come from the indexes and can be wrong. A record's presence says nothing about whether a compound works or is safe. PubMed data via NCBI E-utilities; see NCBI policies.